{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-033933","form_type":"8-K","ticker":"KOD","cik":"0001468748","company_name":"Kodiak Sciences Inc.","filed_at":"2023-07-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.014693+00:00","generated_at":"2026-06-13T04:10:49.504948+00:00","sec_items":["2.02","8.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Kodiak discontinues tarcocimab after Phase 3 DME studies fail to meet endpoints; DAYLIGHT meets primary endpoint","bullets":["Cash and equivalents $379M as of June 30, 2023 (unaudited).","DAYLIGHT study in wet AMD met primary endpoint of non‑inferior visual acuity gains vs aflibercept.","GLEAM and GLIMMER DME studies did not meet primary efficacy endpoint; tarcocimab letters gained 6.4 vs 10.3 (GLEAM) and 7.4 vs 12.2 (GLIMMER).","Cataract adverse events at 19% on tarcocimab vs 9% on aflibercept in pooled DME safety population; no vasculitis or occlusion.","Company discontinues further development of tarcocimab based on these data."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-033933","json":"https://secwatch.observer/filing/0000950170-23-033933.json","markdown":"https://secwatch.observer/filing/0000950170-23-033933.md","text":"https://secwatch.observer/filing/0000950170-23-033933.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1468748/000095017023033933/0000950170-23-033933-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1468748/000095017023033933/kod-20230724.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T04:10:49.504948+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9e2101d69a67a042fcab4b1f922c25f733578a04","claim":"Kodiak Sciences Inc. reported preliminary financial results for the quarter ended June 30, 2023.","evidence_excerpt":"On July 24, 2023, Kodiak Sciences Inc. (“Kodiak,” or the “Company”) reported that, as of June 30, 2023 (unaudited), the Company had approximately $379 million in cash and cash equivalents.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1468748/000095017023033933/0000950170-23-033933-index.htm","confidence":0.7,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended June 30, 2023"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}